Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of IONIS GHR-LRX in acromegaly patients on long-acting somatostatin receptor ligands
2019-000591-42Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cimdelirsen in acromegaly, sponsored by Ionis Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Apr 2019; status: completed.
02
Drugs
cimdelirsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2019-000591-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000591-42.